Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies
Pooled result · MortalityResult — go to the resultHazard ratio 4.38 95% CI 3.76–5.11Authors' conclusion
Compared with the non-HBR population, HBR patients experienced worse 4-year outcomes after percutaneous coronary intervention with cobalt-chromium everolimus-eluting stent. Both CTE and MB had a significant impact on subsequent risk of mortality irrespective of bleeding risk.
Study context
- Population
- Patients undergoing PCI with cobalt-chromium everolimus-eluting stent
- Participants
- 10,502 patients · 4 registries
- Comparison
- High bleeding risk (HBR) vs non-HBR
- HBRn = 3,507
Methodological details4 all-comers postapproval registries, stratified data
- 4 all-comers postapproval registries
- Stratified data
Pooled result
Mortality · 4 years
Hazard ratio
4.38
95% CI 3.76–5.11
HBR vs Non-HBR
HR 4.38 (95% CI 3.76–5.11)
As reported in the abstract
Further pooled results
| Outcome | HR (95% CI) | |
|---|---|---|
| Mortality after CTE (MI or definite/probable stent thrombosis) · time-updated covariate | 5.02 (3.93–6.41) | |
| Mortality after MB (TIMI or GUSTO) · time-updated covariate | 4.92 (3.82–6.35) | |
| 0.10.31310Hazard ratio (log scale) |
- Mortality after coronary thrombotic events (CTE) (MI or definite/probable stent thrombosis): interaction P 0.97
- Mortality after major bleeding (MB) (TIMI or GUSTO): interaction P 0.06
Mortality, HBR by Academic Research Consortium criteria
- Results qualitatively similar
Original publication
Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies. Circulation. Published 29 January 2020. doi:10.
Summarised from the published abstract; every number is checked against it